Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ER/PR Positive Breast Cancer Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Triple-Negative Breast Carcinoma, Progesterone Receptor Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Corona, California • Duarte, California • Lancaster, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced May 22, 2026, 12:01 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Anastrozole
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced May 22, 2026, 12:01 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced May 22, 2026, 12:01 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
Interventions
Tamoxifen, Ribociclib, Goserelin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Onapristone
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Zion, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Metastatic Breast Cancer
Interventions
Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 59 Years · Female only
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
35
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Paclitaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced May 22, 2026, 12:01 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer
Interventions
Standard Trimodality Breast Imaging
Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, tamoxifen, triptorelin
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
2,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
139
States / cities
Burbank, California • La Jolla, California • Mission Hills, California + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Neoplasms, Osteoporosis
Interventions
Zoledronic Acid, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
43
States / cities
Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced May 22, 2026, 12:01 AM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions
Entinostat
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, letrozole, fluorescence in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced May 22, 2026, 12:01 AM EDT